Focus: Santen is a specialty biotechnology company focused exclusively on ophthalmology, headquartered in Emeryville, CA with a recently established US presence. The company operates a portfolio of marketed eye-care products alongside a robust pipeline targeting glaucoma, dry eye, presbyopia, and retinal diseases.
Profile data last refreshed 6h ago · AI intelligence enriched 1mo ago
Hot — 138 jobs added in 30d
Net +116 (138 new, 22 removed). Aggressive expansion phase.
Santen offers specialized ophthalmology depth and pipeline momentum but carries execution risk due to patent cliffs and nascent US operations; best suited for candidates prioritizing therapeutic focus over financial visibility.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Established ophthalmic product facing near-term generic competition, likely in allergy or inflammation category.
Help build intelligence for Santen
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Santen's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
NDA-approved ophthalmic agent approaching loss of exclusivity with no disclosed transition strategy.
Third marketed product in near-term LOE category, completing a portfolio at inflection point.
Santen Stock - long-term eye-care strategy under the microscope - AD HOC NEWS
Santen Stock - long-term eye-care strategy under the microscope AD HOC NEWS
Santen Pharmaceutical Adjusts Valuation Amid Mixed Financial Performance Indicators - MarketsMojo
Santen Pharmaceutical Adjusts Valuation Amid Mixed Financial Performance Indicators MarketsMojo
Why Santen’s MyDay daily disposable lenses aim for quiet comfort all day - AD HOC NEWS
Why Santen’s MyDay daily disposable lenses aim for quiet comfort all day AD HOC NEWS
Why Santen’s Diquas eye drops still matter for dry eyes - AD HOC NEWS
Why Santen’s Diquas eye drops still matter for dry eyes AD HOC NEWS
Santen Pharmaceutical Stock (JP3512800005): Shares in focus amid lack of fresh catalysts - AD HOC NEWS
Santen Pharmaceutical Stock (JP3512800005): Shares in focus amid lack of fresh catalysts AD HOC NEWS
Santen Pharmaceutical stock (JP3512800005): eye-care specialist updates investors on earnings and pi - AD HOC NEWS
Santen Pharmaceutical stock (JP3512800005): eye-care specialist updates investors on earnings and pi AD HOC NEWS
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo